SCHEMBL20140419

SCHEMBL20140419

N#Cc1nc(Cc2ccccc2F)c2cccnn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUCY1A1 Q02108 2/20 0.37
GUCY1B1 Q02153 2/20 0.37
KCNH2 Q12809 2/20 0.37
L3MBTL1 Q9Y468 3/20 0.35
TP53 P04637 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KMT2A Q03164 3/20 0.35
GAA P10253 2/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
LMNA P02545 2/20 0.34
TSHR P16473 1/20 0.34
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 2/20 0.34
AR P10275 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
BUB1 O43683 1/20 0.34
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20141604 0.79 AR (0.38) GUCY1A1GUCY1B1KCNH2L3MBTL1TP53
SCHEMBL13738365 0.77 GUCY1A1 (0.46) GUCY1A1GUCY1B1KCNH2L3MBTL1TP53
SCHEMBL20140398 0.75 CYP19A1 (0.34) GUCY1A1GUCY1B1KCNH2L3MBTL1KMT2A
SCHEMBL20140303 0.75 GUCY1A1 (0.44) GUCY1A1GUCY1B1KCNH2L3MBTL1KMT2A
SCHEMBL21787186 0.72 AR (0.38) GUCY1A1GUCY1B1KCNH2TP53SMN1; SMN2
SCHEMBL14746744 0.71 ALDH1A1 (0.36) L3MBTL1TP53SMN1; SMN2KMT2APOLB
SCHEMBL20140324 0.71 PDE4A (0.44) GUCY1A1GUCY1B1KCNH2L3MBTL1SMN1; SMN2
SCHEMBL19480652 0.70 GUCY1A1 (0.46) GUCY1A1GUCY1B1KCNH2L3MBTL1TP53
SCHEMBL13739532 0.69 GUCY1A1 (0.48) GUCY1A1GUCY1B1KCNH2L3MBTL1TP53
SCHEMBL20139911 0.69 AR (0.36) GUCY1A1GUCY1B1KCNH2TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3135/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3222/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3222/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.